Biogen’s Phase II Lupus Success Offers An Additional Viable Pipeline Asset
While Biogen is seeking to diversify its R&D efforts, unexpected good data in two forms of lupus make internally discovered BIIB059 a viable asset to take forward, although Phase III plans are not set.
You may also be interested in...
Canada’s Aurinia Pharmaceuticals expects to file a US NDA in the first half of next year on the use of its next-generation calcineurin inhibitor, voclosporin, in lupus nephritis, a condition with no approved therapies.
Having recovered from a late-stage fail last year, AstraZeneca has fleshed out results from a positive second Phase III trial of anifrolumab which it hopes will be the second new lupus treatment to hit the market in 60 years.
The company has discontinued a Phase II trial for BG00011, which was acquired in its 2012 Stromedix purchase, due to safety issues.